Tessellate BIO Emerges from Stealth - Replimune Group (NASDAQ:REPL), NewAmsterdam Pharma (NASDAQ:NAMS)
The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT)
Source: benzinga.com